{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Hepatic DLT\n\n* ALT or AST \\> 8 × ULN\n* ALT or AST \\> 5 and ≤ 8 × ULN, that fails to return to ≤ Grade 1 within 2 weeks despite medical intervention.\n* TB \\> 5 × ULN.\n* ALT or AST \\> 3 × ULN and concurrent total bilirubin \\> 2 × ULN. Non-Hematologic DLT\n* ≥ Grade 2 episcleritis, uveitis, iritis or any other immune-related eye pain or reduction in visual acuity that requires systemic treatment.\n* ≥ Grade 3 non-hepatic or non-hematologic toxicity with the exceptions noted below.\n\nHematologic DLT\n\n* Grade 4 anemia not explained by underlying disease.\n* Grade 3 febrile neutropenia lasting \\> 48 hours, or Grade 4 febrile neutropenia\n* Grade 4 neutropenia that does not resolve to Grade 3 or less within 5 days of initiation of granulocyte colony stimulating factor.\n* Grade 3 thrombocytopenia associated with clinically significant bleeding.\n* Grade 3 hemolysis","groups":[{"description":"Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W","id":"OG000","title":"Part A - Flat Dosing (AF)"},{"description":"Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W","id":"OG001","title":"Part A - Age/Weight-based Dosing (AW)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in part A","reportingStatus":"POSTED","timeFrame":"1 cycle, defined as 28 days","title":"Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A","type":"PRIMARY","unitOfMeasure":"Participants"}